| Original language | English (US) |
|---|---|
| Article number | e205671 |
| Pages (from-to) | 127-129 |
| Number of pages | 3 |
| Journal | JAMA Oncology |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2021 |
Funding
Funding/Support: This work was supported by the Agency for Healthcare Research and Quality (5R01HS024516), a grant from the Health Care Services Corporation, the Northwestern Institute for Comparative Effectiveness Research in Oncology, and a grant from the National Cancer Institute (T32CA247801). Dr Brajcich is supported by the American College of Surgeons as part of the Clinical Scholars in Residence Program and by a grant from the National Cancer Institute (T32CA247801). Dr Bilimoria is supported by the Agency for Healthcare Research and Quality (5R01HS024516) and by a grant from the Health Care Services Corporation. Conflict of Interest Disclosures: Dr Brajcich reported stock ownership in Nanostring Technologies, Inc. outside the submitted work. Dr Stulberg reported grants from Pacira Pharmaceuticals and the Intuitive Foundation and personal fees from Intuitive Surgical outside the submitted work. Dr Nelson reported consulting fees from Gentex from January 2020 to March 2020. No other disclosures were reported.
ASJC Scopus subject areas
- Oncology
- Cancer Research
